Why Walgreens Boots Alliance Shares Are Plunging Today

Loading...
Loading...
  • Walgreens Boots Alliance Inc's WBA Q2 FY22 sales increased 3% Y/Y to $33.8 billion, up 3.8% on a constant currency basis, beating the consensus of $33.36 billion.
  • Omicron variant of COVID-19 intensified demand for booster shots and tests and drove foot traffic during the winter months.
  • Adjusted EPS reached $1.59, beating the consensus of $1.38
  • Walgreens said same-store sales for retail in the U.S. jumped 14.7%, the largest gain in over 20 years. 
  • Boots UK retail comparable sales are up 22%, with share gains across all major categories.
  • The drugstore chain administered 11.8 million Covid vaccines in the second quarter, bringing over 62.8 million vaccines to date.
  • Adjusted operating income of $1.7 billion, improved 35.9% on a constant currency basis.
  • Walgreens said it is still considering the future of its U.K.-based Boots drugstore chain.
  • Related: Bain Capital Reportedly Eyeing Boots UK Takeover From Walgreens: Report.
  • Guidance: Walgreens Boots Alliance maintains FY22 adjusted EPS guidance of low-single-digit growth.
  • Price Action: WBA shares are down 5.39% at $44.90 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...